Lung Diseases

We are building on a heritage of more than a century in respiratory diseases, with treatments in asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrotic interstitial lung disease. Our R&D approach leverages our deep understanding and extensive expertise in respiratory medicine, inflammation and fibrosis to develop the next generation of therapies for patients with a broad range of lung diseases who have a high unmet medical need.

Our scientific expertise includes mechanisms and targets that underpin chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, systemic sclerosis and asthma.

Scientists in our dedicated respiratory research and development centers, located in the USA and Germany, have extensive R&D expertise in the discovery and clinical validation of novel mechanisms of action. Together with our academic and industry partners, they are working to offer patients and doctors new therapeutic options to treat chronic inflammatory and fibrotic diseases of the lungs.

We focus on core scientific themes to arrest the trajectory of chronic inflammatory and fibrotic diseases of the lungs:

• Mucosal barrier injury and repair
• Lung repair and regeneration
• Aberrant tissue remodelling

Downloads

[View PDF
Opens in new tab](/content/us/pdf/partnering-immunology-respiratory-diseasespdf "Our Respiratory Partnering Interests"/index.html)

DOWNLOAD PDF (317.61 KB)

Our Respiratory Partnering Interests

[View PDF
Opens in new tab](/content/us/pdf/partnering-immunology-respiratory-diseasespdf/index.html)

References